Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations

PharmaNutrition

Volumn 1, Issue 1, 2013, Pages 10-12

  Visioli, F ^a   Reilly, M M ^b   Rimoldi, M ^c   Solari, A ^c   Pareyson, D ^c  

^a IMDEA FOOD INSTITUTE   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Ascorbic acid; Charcot Marie Tooth disease; Myelin; Neuromuscular disorders

Indexed keywords

ASCORBIC ACID; TRACE ELEMENT;

ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROINTESTINAL SYMPTOM; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCURVY; SINGLE DRUG DOSE; VITAMIN SUPPLEMENTATION;

EID: 84877980543     PISSN: 22134344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phanu.2012.10.001     Document Type: Article

References (23)

1. Pareyson D., Solari A. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?. Lancet Neurology 2009, 8:1075-1077.
2. Passage E., Norreel J.C., Noack-Fraissignes P., Sanguedolce V., Pizant J., Thirion X., et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nature Medicine 2004, 10:396-401.
3. Kaya F., Belin S., Bourgeois P., Micaleff J., Blin O., Fontes M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscular Disorders 2007, 17:248-253.
4. Burns J., Ouvrier R.A., Yiu E.M., Joseph P.D., Kornberg A.J., Fahey M.C., et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurology 2009, 8:537-544.
5. Micallef J., Attarian S., Dubourg O., Gonnaud P.M., Hogrel J.Y., Stojkovic T., et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology 2009, 8:1103-1110.
6. Verhamme C., de Haan R.J., Vermeulen M., Baas F., de Visser M., van Schaik I.N. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Medicine 2009, 7:70.
7. Pareyson D., Reilly M.M., Schenone A., Fabrizi G.M., Cavallaro T., Santoro L., et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology 2011, 10:320-328.
8. Reilly M.M., Shy M.E., Muntoni F., Pareyson D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscular Disorders 2010, 20:839-846.
9. Hodges R.E., Baker E.M., Hood J., Sauberlich H.E., March S.C. Experimental scurvy in man. American Journal of Clinical Nutrition 1969, 22:535-548.
10. Levine M., Conry-Cantilena C., Wang Y., Welch R.W., Washko P.W., Dhariwal K.R., et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3704-3709.
11. Padayatty S.J., Sun H., Wang Y., Riordan H.D., Hewitt S.M., Katz A., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Annals of Internal Medicine 2004, 140:533-537.
12. Padayatty S.J., Sun A.Y., Chen Q., Espey M.G., Drisko J., Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS ONE 2010, 5:e11414.
13. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB Journal 2008, 22:659-661.
14. Smith A.R., Visioli F., Hagen T.M. Vitamin C matters: increased oxidative stress in cultured human aortic endothelial cells without supplemental ascorbic acid. FASEB Journal 2002, 16:1102-1104.
15. Halliwell B., Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. British Journal of Pharmacology 2004, 142:231-255.
16. Gess B., Lohmann C., Halfter H., Young P. Sodium-dependent vitamin C transporter 2 (SVCT2) is necessary for the uptake of l-ascorbic acid into Schwann cells. Glia 2010, 58:287-299.
17. Michels A.J., Hagen T.M., Frei B. A new twist on an old vitamin: human polymorphisms in the gene encoding the sodium-dependent vitamin C transporter 1. American Journal of Clinical Nutrition 2010, 92:271-272.
18. Carr A.C., Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. American Journal of Clinical Nutrition 1999, 69:1086-1107.
19. Frei B., Trabe M.G. The new US Dietary Reference Intakes for vitamins C and E. Redox Report 2001, 6:5-9.
20. Toth C. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients. Acta Neurologica Scandinavica 2009, 120:134-138.
21. Halliwell B. Vitamin C: antioxidant or pro-oxidant in vivo?. Free Radical Research 1996, 25:439-454.
22. Food and Nutrition Board IoM. Vitamin C. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington D.C.: National Academy Press; 2000;95-185.
23. Hathcock J.N., Azzi A., Blumberg J., Bray T., Dickinson A., Frei B., et al. Vitamins E and C are safe across a broad range of intakes. American Journal of Clinical Nutrition 2005, 81:736-745.